Literature DB >> 8838458

Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes.

P Avenet1, J Léonardon, F Besnard, D Graham, J Frost, H Depoortere, S Z Langer, B Scatton.   

Abstract

The NMDA receptor antagonist ifenprodil contains two asymmetric centres which give rise to four stereoisomeric forms of this molecule. The inhibitory effects of each of these stereoisomers on recombinant NMDA receptors expressed from NR1A/NR2A and NR1A/NR2B subunit combinations were studied in Xenopus oocytes by voltage-clamp recording. All four ifenprodil stereoisomers were potent antagonists at NR1A/NR2B (IC50 < 0.8 microM), but weak antagonists at NR1A/NR2A receptors (IC50 > 100 microM). In heteromeric NR1A/NR2B receptors, (+) erythro- and (-) threo-ifenprodil (IC50 0.21 and 0.22 microM, respectively) were about 4 times more potent than (-) erythro- and (+) threo-ifenprodil (IC50 0.81 and 0.76, respectively). These results show that the stereoisomers of ifenprodil exhibit a weak though significant stereoselectivity at the NR1A/NR2B NMDA receptor subtype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8838458     DOI: 10.1016/0014-2999(95)00700-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat.

Authors:  A H Shin; H J Kim; S A Thayer
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators.

Authors:  Pieter B Burger; Hongjie Yuan; Erkan Karakas; Matthew Geballe; Hiro Furukawa; Dennis C Liotta; James P Snyder; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2012-05-17       Impact factor: 4.436

3.  Differential binding properties of [3H]dextrorphan and [3H]MK-801 in heterologously expressed NMDA receptors.

Authors:  K T LePage; J E Ishmael; C M Low; S F Traynelis; T F Murray
Journal:  Neuropharmacology       Date:  2005-04-01       Impact factor: 5.250

4.  Both ethanol and ifenprodil inhibit NMDA-evoked release of various neurotransmitters at different, yet proportional potency: potential relation to NMDA receptor subunit composition.

Authors:  K Fink; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

5.  NMDA receptor characterization and subunit expression in rat cultured mesencephalic neurones.

Authors:  C Allgaier; P Scheibler; D Müller; T J Feuerstein; P Illes
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

6.  Sex-related differences in NMDA-evoked rat masseter muscle afferent discharge result from estrogen-mediated modulation of peripheral NMDA receptor activity.

Authors:  X-D Dong; M K Mann; U Kumar; P Svensson; L Arendt-Nielsen; J W Hu; B J Sessle; B E Cairns
Journal:  Neuroscience       Date:  2007-03-26       Impact factor: 3.590

Review 7.  A structural biology perspective on NMDA receptor pharmacology and function.

Authors:  Michael C Regan; Annabel Romero-Hernandez; Hiro Furukawa
Journal:  Curr Opin Struct Biol       Date:  2015-08-15       Impact factor: 6.809

8.  NMDA receptors in primary afferents require phosphorylation by Src family kinases to induce substance P release in the rat spinal cord.

Authors:  W Chen; G Zhang; J C G Marvizón
Journal:  Neuroscience       Date:  2010-01-13       Impact factor: 3.590

9.  Human immunodeficiency virus-1 Tat protein increases the number of inhibitory synapses between hippocampal neurons in culture.

Authors:  Nicholas J Hargus; Stanley A Thayer
Journal:  J Neurosci       Date:  2013-11-06       Impact factor: 6.167

Review 10.  Glutamate receptors and Parkinson's disease: opportunities for intervention.

Authors:  Michael J Marino; Ornella Valenti; P Jeffrey Conn
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.